Hepatitis C Drugs Will 'Strain Budgets' at Current Prices: Study

March 16, 2015 9:00 PM

2 0

MONDAY, March 16, 2015 (HealthDay News) -- New hepatitis C drugs promise cure rates above 90 percent, but could prove to be budget-busters for public and private health insurers, a new analysis finds.

Recently approved drugs for chronic hepatitis C have been heralded as a breakthrough that could make the liver disease "rare" in the United States. But with prices topping $1,000 per pill, government and private insurers are balking -- often putting limits on which patients qualify for coverage.

Also read: Korea's President Might Be Impeached and its Markets Are Surging

Read more

To category page

Loading...